Results 11 to 20 of about 32,734 (287)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2 [PDF]

Nature Communications, 2022
Different homologous and heterologous vaccination regimens have been used for COVID-19. Here the authors show in a cohort analysis from Catalonia that heterologous vaccination with ChAdOx1 followed by BNT162b2 has better vaccine effectiveness than two ...
Eduardo Hermosilla, Ermengol Coma, Junqing Xie, Shuo Feng, Carmen Cabezas, Leonardo Méndez-Boo, Francesc Fina, Elisabet Ballo, Montserrat Martínez, Manuel Medina-Peralta, Josep Maria Argimon, Daniel Prieto-Alhambra   +11 more
doaj   +3 more sources

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice [PDF]

Nature Communications, 2021
Heterologous vaccination regimens for COVID-19 could be useful for example if there is a shortage of one vaccine type. Here, Spencer et al. show that heterologous vaccination with a self-amplifying RNA vaccine and an adenoviral vectored vaccine performs ...
Alexandra J. Spencer, Paul F. McKay, Sandra Belij-Rammerstorfer, Marta Ulaszewska, Cameron D. Bissett, Kai Hu, Karnyart Samnuan, Anna K. Blakney, Daniel Wright, Hannah R. Sharpe, Ciaran Gilbride, Adam Truby, Elizabeth R. Allen, Sarah C. Gilbert, Robin J. Shattock, Teresa Lambe   +15 more
doaj   +4 more sources

The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2

Vaccines, 2021
Coronavirus Disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the global challenge. Reaching global herd immunity will help end the COVID-19 pandemic.
Tzu-Chuan Ho, Yi-Ming Arthur Chen, Hung-Pin Chan, Chin-Chuan Chang, Kuo-Pin Chuang, Che-Hsin Lee, Cheng-Hui Yuan, Yu-Chang Tyan, Ming-Hui Yang   +8 more
doaj   +3 more sources

Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2 [PDF]

Vaccines (Basel), 2022
Within a year after the emergence of SARS-CoV-2, several vaccines had been developed, clinically evaluated, proven to be efficacious in preventing symptomatic disease, and licensed for global use.
Johann Volzke, Emil C. Reisinger, Franz Mai, Brigitte Müller-Hilke, Michael Müller   +4 more
core   +2 more sources

Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium

Vaccines, 2023
We investigated effectiveness of (1) mRNA booster vaccination versus primary vaccination only and (2) heterologous (viral vector–mRNA) versus homologous (mRNA–mRNA) prime-boost vaccination against severe outcomes of BA.1, BA.2, BA.4 or BA.5 Omicron ...
Marjan Meurisse, Lucy Catteau, Joris A. F. van Loenhout, Toon Braeye, Laurane De Mot, Ben Serrien, Koen Blot, Emilie Cauët, Herman Van Oyen, Lize Cuypers, Belgian Collaborative Group on COVID-19 Hospital Surveillance, COVID-19 Genomics Belgium Consortium, Annie Robert, Nina Van Goethem   +13 more
doaj   +2 more sources

Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine

Vaccines, 2022
No data regarding the efficacy of a third mRNA vaccine for solid cancer patients previously primed with the heterologous CoronoVac/ChAdOx1 vaccination implemented in Thailand during the shortage of vaccine supply are available. Forty-four cancer patients
Sutima Luangdilok, Passakorn Wanchaijiraboon, Nussara Pakvisal, Thiti Susiriwatananont, Nicha Zungsontiporn, Virote Sriuranpong, Panot Sainamthip, Nungruthai Suntronwong, Preeyaporn Vichaiwattana, Nasamon Wanlapakorn, Yong Poovorawan, Nattaya Teeyapun, Suebpong Tanasanvimon   +12 more
doaj   +2 more sources

Heterologous prime-boost vaccination drives stromal activation and adaptive immunity against SARS-CoV-2 variants

Frontiers in Immunology
Heterologous vaccination strategies have shown superior efficacy over homologous regimens in clinical studies, but the underlying immunological mechanisms remain incompletely understood.
Ji Hyang Jeon, Ji Hyang Jeon, Seongryong Kim, Seo-Yeon Kim, Kwang-Soo Shin, Bongju Park, Soojeong Chang, Chang-Yuil Kang, You-Jin Kim, Jong-Eun Park, Sungsu Youk, Sungsu Youk, Dokeun Kim, Jinah Yeo   +13 more
doaj   +2 more sources

Multivalent and Sequential Heterologous Spike Protein Vaccinations Effectively Induce Protective Humoral Immunity against SARS-CoV-2 Variants

Vaccines
The emergence of new SARS-CoV-2 variants continues to cause challenging problems for the effective control of COVID-19. In this study, we tested the hypothesis of whether a strategy of multivalent and sequential heterologous spike protein vaccinations ...
Rong Liu, Janhavi P. Natekar, Ki-Hye Kim, Heather Pathak, Noopur Bhatnagar, Jannatul Ruhan Raha, Bo Ryoung Park, Anchala Guglani, Chong Hyun Shin, Mukesh Kumar, Sang-Moo Kang   +10 more
doaj   +2 more sources

Hybrid immunity strategies: heterologous vaccination combined with natural SARS-CoV-2 infection [PDF]

Frontiers in Medicine
The continuous evolution of SARS-CoV-2 poses a significant challenge to existing immune barriers, highlighting the limitations of single-modality immunization.
Yuan Huang, Xiaolu Zhang, Ruixia Miao, Jing Wang, Xuan Xi, Heng Pan, Yan Lu, Dehong Li   +7 more
doaj   +2 more sources

Heterologous vaccine regimens against COVID-19 [PDF]

The Lancet, 2021
The rapid development of vaccines against COVID-19 is the biggest achievement of science in the fight against the pandemic. Although the efficacy and safety of all approved vaccines have been demonstrated in large clinical trials, recent safety signals have been reported, highlighting the importance of post-marketing surveillance with study populations
Duarte-Salles, Talita, Prieto-Alhambra, Daniel, Prieto Alhambra, D. (Dani)   +2 more
openaire   +2 more sources